TAFI (Thrombin Activatable Fibrinolysis Inhibitor) - White Paper
18.08.2022
As a researcher in hemostasis you might be interested in latest scientific information on TAFI (Thrombin Activatable Fibrinolysis Inhibitor).
TAFI is activated by Thrombin and plays an important role in hemostasis and fibrinolysis.
Current research has provided evidence for the importance of TAFI in certain clinical conditions:
- The role of TAFI in acute myocardial infarction (AMI)
- Association with Acute Pulmonary Embolism
- Delayed fibrinolysis in connection with coinherited TAFI deficiency
- The bleeding phenotype in patients with severe hemophilia A
- Plasmin generation on thrombin-activated platelets
- As a target for anti-thrombotic therapy
- Vascular remodeling after hemophilic joint bleeding
- Certain forms of inflammation
We have compiled an updated White Paper with scientific TAFI publications and information on our TAFI Activity Assay.
This assay is a functional chromogenic assay for the determination of Thrombin Activatable Fibrinolysis Inhibitor (TAFI), which has been widely used by the scientific community in specialty coagulation research and development.
If you are interested in this information compilation please send an email to info@loxo.de. We will be happy to provide this to you.
*Kindly note that some products might not be available for sale in your market via LOXO. We would however refer you to your local supplier.
We are looking forward to your response!
- Please call us at: +49 6221 868023
- Or send a Fax: +49 6221 8680255
- Or send an E-Mail: info@loxo.de
Are you looking for additional products?
- Please use the search function of our web page
With best regards
Your LOXO - Team